Sign in
TerminatedPhase 2

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Key facts

Who runs it
Thomas Jefferson University
Where
Philadelphia, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
6 people enrolled
Started
16 Nov 2022
Ended
24 Oct 2025
Type of study
Interventional
Treatments tested
  • MRI-guided Intensity-Modulated Radiation Therapy
  • Antiandrogen Therapy
  • PSMA PET Scan
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Bone Scan
  • Biospecimen Collection
  • Quality-of-Life Assessment
Record updated
3 March 2026
Why it stopped
Loss of required MRI resources needed to conduct protocol-specified procedures

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age: above 18 years
  • Participants must be histologically proven, adenocarcinoma prostate
  • Localized to the prostate without positive pelvic lymph node involvement
  • No distant metastatic disease assessed by pretreatment PSMA PET or bone scan and CT scan
  • High risk prostate cancer as defined by National Comprehensive Cancer Network (NCCN): Gleason score of 8- 10, clinical stage T3a or higher, or prostate specific antigen (PSA) > 20 ng/mL
  • Ability to receive long term hormone therapy
  • Karnofsky performance score (KPS) > 70
  • No prior history of therapeutic irradiation to pelvis
  • Patient willing and reliable for follow-up and quality of life (QOL)
  • English speaking/reading

Who cannot take part

  • Previous radiation therapy (RT) to prostate or prostatectomy
  • A previous trans-urethral resection of the prostate (TURP)
  • Severe urinary symptoms or with severe International Prostate Symptom Score (IPSS) score despite being on hormonal therapy for 6 months which in the opinion of the physician precludes RT
  • Any contraindication to radiotherapy such as inflammatory bowel disease
  • Life expectancy < 2 years
  • Evidence of distant or pelvic metastasis at any time since presentation
  • Patients with known obstructive symptoms with stricture

Where in United States

  • Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladelphia, United States

About the trial

What the trial wants to find out

This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time directly to diseased tissue, reducing damage to healthy tissue. Using MRI-guided radiation therapy on areas of the prostate and pelvic lymph nodes may shorten overall treatment time compared to the longer standard of care therapy and may reduce the number and/or duration of side effects.

The group in the trial

  • Treatment (MRI-guided IMRT, ADT)Treatment being tested

    Patients undergo MRI-guided IMRT on study and receive SOC ADT throughout the trial. Patients may also undergo PSMA PET, CT, MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.

    Treatment: MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, Biospecimen Collection, and Quality-of-Life Assessment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Study of Extreme Hypofractionation Including Pelvic Nodes for High Risk Prostate Cancer Using MgRT (MRI Guided Radiation Therapy)
Record updated
3 March 2026
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer (NCT05676463) – Frontlight Research